Show simple item record

dc.contributor.authorThomas, M
dc.contributor.authorThatcher, Nick
dc.contributor.authorGoldschmidt, J
dc.contributor.authorOhe, Y
dc.contributor.authorMcBride, HJ
dc.contributor.authorHanes, V
dc.date.accessioned2019-11-19T16:01:00Z
dc.date.available2019-11-19T16:01:00Z
dc.date.issued2019en
dc.identifier.citationThomas M, Thatcher N, Goldschmidt J, Ohe Y, McBride HJ, Hanes V. Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar. Immunotherapy. 2019;11(15):1337-51.en
dc.identifier.pmid31556762en
dc.identifier.doi10.2217/imt-2019-0125en
dc.identifier.urihttp://hdl.handle.net/10541/622413
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.2217/imt-2019-0125en
dc.titleTotality of evidence in the development of ABP 215, an approved bevacizumab biosimilaren
dc.typeArticleen
dc.contributor.departmentInternistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitatsklinikum Heidelberg, Translational Lung Research Center, Heidelberg, Germanyen
dc.identifier.journalImmunotherapyen
refterms.dateFOA2020-01-05T19:38:23Z


Files in this item

Thumbnail
Name:
imt-2019-0125.pdf
Size:
2.132Mb
Format:
PDF
Description:
Full text, Open Access article

This item appears in the following Collection(s)

Show simple item record